NCT00513578Unknown2 期
Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS
The Vaccine Company2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2007年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Immunologic response after four injections of vaccine formulation as determined by an increase in the absolute PR1-HLA-A2 tetramer count by at least 0.5/μl
研究概览
简要总结
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with low-risk or intermediate-risk myelodysplastic syndrome.
详细描述
OBJECTIVES:
Primary
- To determine the immunologic response, using a PR1-HLA-A2 tetramer assay, to 4 subcutaneous injections of PR1 leukemia peptide vaccine formulated in incomplete Freund's adjuvant (IFA) followed by sargramostim (GM-CSF) in patients with low- and intermediate-1-risk myelodysplastic syndromes.
Secondary
- To determine if non-immunologic responders to 4 subcutaneous injections of PR1 leukemia peptide vaccine formulated in IFA followed by GM-CSF can be converted to immunologic responders by administering 4 additional doses of this treatment.
- To determine the clinical response to 4 or 8 subcutaneous injections of this vaccine.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Inclusion criteria:
- •Diagnosis of myelodysplastic syndromes (MDS) and must meet all of the following criteria:
- •FAB class refractory anemia (RA), RA with excess blasts (RAEB), or RA with ringed sideroblasts (RARS)
- •WHO Classification RA, RARS, refractory cytopenia with multilineage dysplasia (RCMD), RCMD with ringed sideroblasts, or RAEB-1
- •Less than 20% blasts on marrow aspirate
- •IPSS risks groups intermediate-1- OR transfusion dependent low-risk
- •Patients with de novo or therapy-related MDS eligible
- •HLA-A2 positive at one allele
排除标准
- •RAEB in transformation or RAEB-2
- •Marrow blasts on aspirate ≥ 20%
- •Blood blasts > 1%
- •Inaspirable bone marrow
- •History or current myelosclerosis occupying > 30% of marrow space
- •History of acute myeloid leukemia
- •Other causes of cytopenia not related to MDS (i.e., gastrointestinal blood loss)
- •PATIENT CHARACTERISTICS:
- •Inclusion criteria:
- •ECOG performance status 0 or 1
- •Women of childbearing potential must have a negative serum pregnancy test within 30 days of starting study drug
- •Male or female of child-bearing potential must agree to use adequate contraceptive methods
- •Serum bilirubin < 2 mg/mL
- •Creatinine ≤ 1.5 mg/mL
- •ALT < 2 times upper normal limit
- •Antineutrophil cytoplasmic antibody (cANCA) negative
- •Exclusion criteria:
- •Pregnant or lactating
- •Iron absence on marrow examination or transferrin saturation < 20% and serum ferritin < 50ng/mL
- •B12 deficiency
- •Folate deficiency
- •History of immune-related hematological disorder (i.e., idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia)
- •Life expectancy severely limited by diseases other than MDS
- •Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for ≥ 5 years
- •Known allergy to incomplete Freund's adjuvant
- •Hypercalcemia
- •Progressive viral or bacterial infection
- •All infections must be resolved and the patient has remained afebrile for seven days without antibiotics
- •Cardiac disease of symptomatic nature or cardiac ejection fraction < 40%
- •History of Wegener granulomatosis or vasculitis
- •Symptomatic pulmonary disease or FEV_1, FVC, and DLCO ≤ 50% predicted
- •History of HIV positivity or AIDS
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form or that will place the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret the data
- •PRIOR CONCURRENT THERAPY:
- •Exclusion criteria:
- •Has received specific therapy for MDS within the past 4 weeks
- •Prior allogeneic or syngeneic transplant
- •Prior solid organ transplant
- •Chronic use (> 2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to > 10 mg/day of prednisone) within 30 days of the first day of study drug treatment
- •Topical and inhaled corticosteroids are permitted
- •Experimental therapy, cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
- •Treatment with androgenic hormones, danazol, colony-stimulating factors, erythropoietin, thalidomide, arsenic trioxide or other agents used to treat MDS within four weeks of the first day of study treatment
- •Prior vaccine therapy for MDS
- •Prohibited medications during study, including any of the following:
- •Systemic steroids except as required for transfusion reactions
- •Chemotherapy or other investigational drugs
- •Sargramostim (GM-CSF) (except as part of study regimen)
- •Filgrastim (G-CSF)
- •Interleukin-11
结局指标
主要结局
Immunologic response after four injections of vaccine formulation as determined by an increase in the absolute PR1-HLA-A2 tetramer count by at least 0.5/μl
次要结局
- Clinical response as determined by modified IWG criteria
- Conversion of non-immunologic responders to immunologic responders by administering 4 additional doses of vaccine
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaLeukemiaNCT00466726Gruppo Italiano Malattie EMatologiche dell'Adulto57
Unknown
3 期
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in RemissionLeukemiaNCT00454168The Vaccine Company244
Unknown
2 期
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerLung CancerNCT00104780Epimmune
已完成
1 期
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaMalignant MesotheliomaMyelodysplastic SyndromesLung CancerLeukemiaPrimary Peritoneal Cavity CancerNCT00398138Memorial Sloan Kettering Cancer Center22
终止
2 期
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaLeukemiaNCT00428077OHSU Knight Cancer Institute4